GLP-1 May Become the Biggest Catalyst the Body Care Industry Has Ever Seen
GLP-1 medications have sparked one of the biggest conversations in beauty over the past year, but much of that discussion has centered on the face. Headlines have focused on volume loss, changes in facial appearance, and how brands are responding to consumers experiencing rapid weight loss.
Beekman 1802's latest launch suggests the next chapter of that conversation may be happening below the neck. The brand recently expanded its Milk RX line with a body cream formulated to address crepey skin, loss of elasticity, and skin changes associated with aging, rapid weight loss, and GLP-1 use. The timing feels significant. Body care has become one of beauty's fastest-evolving categories, with brands across the industry investing in more sophisticated formulations, active ingredients, and clinically backed products designed for the body. Companies like Summer Fridays, Soft Services, Nécessaire, OSEA, and others have helped move body care beyond basic moisturization, and consumers are responding, they're looking for products that treat the body with the same level of science and innovation they've come to expect from facial skincare.
Throughout my doctoral research, one pattern has consistently emerged. Consumers don't organize their routines the way the beauty industry organizes its categories. They don't think in terms of facial skincare, body care, hair care, or wellness. They think about taking care of their skin, maintaining routines that fit naturally into their lives, and investing in products that help them look and feel their best. That difference is beginning to reshape where innovation happens.
Historically, facial skincare has been where beauty's biggest scientific breakthroughs occurred. Peptides, ceramides, retinoids, barrier science, and clinically validated formulations transformed the way consumers cared for their faces. Body care, by comparison, remained relatively simple, centered on hydration, fragrance, and basic moisturization.
That gap is closing quickly. What makes Beekman's launch particularly compelling is that it responds to a very specific moment in consumer behavior. GLP-1 medications have brought conversations around skin laxity and loss of elasticity into the mainstream, but those concerns extend well beyond one group of consumers. Healthy aging, postpartum skin changes, weight fluctuations, and overall skin resilience have become much larger conversations across beauty. Rather than treating body care as a separate category, Beekman is responding to those concerns with the same scientific approach consumers have come to expect from facial skincare.
Vogue recently identified advanced body care as one of the defining beauty trends of 2026, highlighting the growing use of targeted treatments and skincare-inspired formulations below the neck. Beekman's latest launch doesn't create that trend, but it reinforces where the category is heading. As consumers increasingly think about skin as one continuous organ rather than separate categories, the distinction between facial skincare and body care becomes less meaningful. Innovation will follow consumer needs rather than traditional retail categories.
I believe the future of body care will be defined by science, personalization, and clinical credibility, not because consumers suddenly want more body products, but because they expect the same level of innovation everywhere they care for their skin. Beekman 1802's latest launch may be one product, but I think it offers an early glimpse into where the entire category is headed.
Dania Khalife
